Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Receivables - Net: 2021-2025

Historic Receivables - Net for Apellis Pharmaceuticals (APLS) over the last 5 years, with Sep 2025 value amounting to $345.5 million.

  • Apellis Pharmaceuticals' Receivables - Net rose 23.84% to $345.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $345.5 million, marking a year-over-year increase of 23.84%. This contributed to the annual value of $264.9 million for FY2024, which is 28.33% up from last year.
  • As of Q3 2025, Apellis Pharmaceuticals' Receivables - Net stood at $345.5 million, which was up 61.37% from $214.1 million recorded in Q2 2025.
  • In the past 5 years, Apellis Pharmaceuticals' Receivables - Net ranged from a high of $345.5 million in Q3 2025 and a low of $719,000 during Q2 2021.
  • In the last 3 years, Apellis Pharmaceuticals' Receivables - Net had a median value of $235.2 million in 2025 and averaged $220.8 million.
  • Per our database at Business Quant, Apellis Pharmaceuticals' Receivables - Net soared by 2,571.70% in 2023 and then decreased by 29.66% in 2025.
  • Over the past 5 years, Apellis Pharmaceuticals' Receivables - Net (Quarterly) stood at $10.1 million in 2021, then fell by 23.52% to $7.7 million in 2022, then surged by 2,571.70% to $206.4 million in 2023, then grew by 28.33% to $264.9 million in 2024, then rose by 23.84% to $345.5 million in 2025.
  • Its Receivables - Net stands at $345.5 million for Q3 2025, versus $214.1 million for Q2 2025 and $235.2 million for Q1 2025.